DDInter1376 DDInter1105
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lurbinectedin may lead to a major life threatening interaction when taken with Ribociclib
Lurbinectedin may lead to a major life threatening interaction when taken with Upadacitinib